Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

3.0K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
3.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

3.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
3.8K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

4.5K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.

NEJM evidence·2026
Same author

Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation.

Transplantation and cellular therapy·2025
Same author

Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experience.

Bone marrow transplantation·2025
Same author

Clericuzio-type poikiloderma with neutropenia and leg ulceration.

JAAD case reports·2024
Same author

Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline.

British journal of haematology·2024
Same author

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Haematology·2023

Related Experiment Video

Updated: May 3, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K

Allogeneic stem cell transplantation in MDS: how? When?

Uwe Platzbecker1, Ghulam Mufti2

  • 1Universitätsklinikum "Carl-Gustav-Carus" der TUD, Medizinische Klinik I, Fetscherstraße 74, 01307 Dresden, Germany.

Best Practice & Research. Clinical Haematology
|February 11, 2014
PubMed
Summary

Allogeneic stem cell transplants offer a cure for some myelodysplastic syndromes (MDS) patients. Optimizing pre- and post-transplant care is crucial for long-term MDS control and quality of life.

Keywords:
allogeneic hematopoietic stem cell transplantationhypomethylating agents

More Related Videos

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.9K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

17.2K

Related Experiment Videos

Last Updated: May 3, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.9K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

17.2K

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Myelodysplastic syndromes (MDS) primarily affect the elderly, often excluding them from intensive treatments like allogeneic hematopoietic stem cell transplantation (allo-HCT).
  • Innovative therapies, including hypomethylating agents (HMA), have expanded treatment options for MDS.
  • Reduced-intensity conditioning has lowered early mortality, increasing allo-HCT utilization in MDS.

Purpose of the Study:

  • To review the current landscape of allo-HCT for MDS.
  • To highlight challenges in patient selection and post-transplant care.
  • To emphasize strategies for optimizing outcomes in MDS patients undergoing allo-HCT.

Main Methods:

  • Review of current literature and clinical practices in allo-HCT for MDS.
  • Analysis of factors influencing morbidity and mortality post-transplant.
  • Discussion of treatment optimization strategies.

Main Results:

  • Allo-HCT can cure a subset of MDS patients.
  • Graft-versus-host disease and relapse remain significant challenges.
  • Improved patient selection and optimized pre- and post-transplant management are key.

Conclusions:

  • While allo-HCT offers a potential cure for MDS, careful patient selection is paramount.
  • Addressing late complications like graft-versus-host disease and relapse is critical for improving long-term survival.
  • Optimizing the entire transplant process, from pre-transplant conditioning to post-transplant support, is essential for achieving durable disease control and maintaining patient quality of life.